Asia Deal Watch: Cytokinetics Licenses China Rights For Omecamtiv To Ji Xing

Drug Is Second Asset Under Companies' Partnership

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.